- Home
- GLRE vs IGMS Comparison
GLRE vs IGMS Comparison
Compare GLRE & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- IGMS
- Stock Information
- Founded
- GLRE 2004
- IGMS 1993
- Country
- GLRE Cayman Islands
- IGMS United States
- Employees
- GLRE N/A
- IGMS N/A
- Industry
- GLRE Property-Casualty Insurers
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- GLRE Finance
- IGMS Health Care
- Exchange
- GLRE Nasdaq
- IGMS Nasdaq
- Market Cap
- GLRE 471.2M
- IGMS 528.6M
- IPO Year
- GLRE 2007
- IGMS 2019
- Fundamental
- Price
- GLRE $14.49
- IGMS $7.39
- Analyst Decision
- GLRE
- IGMS Buy
- Analyst Count
- GLRE 0
- IGMS 8
- Target Price
- GLRE N/A
- IGMS $16.25
- AVG Volume (30 Days)
- GLRE 83.1K
- IGMS 213.0K
- Earning Date
- GLRE 11-04-2024
- IGMS 11-08-2024
- Dividend Yield
- GLRE N/A
- IGMS N/A
- EPS Growth
- GLRE N/A
- IGMS N/A
- EPS
- GLRE 2.53
- IGMS N/A
- Revenue
- GLRE $702,254,000.00
- IGMS $2,918,000.00
- Revenue This Year
- GLRE N/A
- IGMS $386.95
- Revenue Next Year
- GLRE N/A
- IGMS N/A
- P/E Ratio
- GLRE $5.76
- IGMS N/A
- Revenue Growth
- GLRE 8.96
- IGMS 57.64
- 52 Week Low
- GLRE $10.95
- IGMS $6.17
- 52 Week High
- GLRE $15.82
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- GLRE 43.86
- IGMS 31.53
- Support Level
- GLRE $14.33
- IGMS $7.00
- Resistance Level
- GLRE $15.02
- IGMS $10.80
- Average True Range (ATR)
- GLRE 0.26
- IGMS 0.96
- MACD
- GLRE -0.10
- IGMS -0.10
- Stochastic Oscillator
- GLRE 17.98
- IGMS 8.33
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed, and income from investments.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.